Literature DB >> 20211214

Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation.

Nataraju Angaswamy1, Deepti Saini, Sabarinathan Ramachandran, Dilip S Nath, Donna Phelan, Ramsey Hachem, Elbert Trulock, G Alexander Patterson, T Mohanakumar.   

Abstract

The development of antibodies (Abs) to major histocompatibility (MHC) class I-related chain A (MICA) and human leukocyte antigen (HLA) and their role in the immunopathogenesis of chronic rejection (bronchiolitis obliterans syndrome [BOS]) after human lung transplantation (LTx) was analyzed. Sera from 80 LTx recipients were analyzed for anti-MICA and anti-HLA Abs using Luminex and flow PRA (panel reactive assay). Development of Abs either to MICA alone or MICA and HLA together significantly correlated (p < 0.01) with development of BOS. Kinetic analysis in the post-LTx period revealed that development of anti-HLA Abs (7.6 +/- 4.7 months) preceded the development of anti-MICA Abs (10.0 +/- 3.5 months). Abs to MICA alleles (*001 and *009) developed approximately 6 months after LTx and peak titers were present at the time of clinical diagnosis of BOS (16.3 +/- 2.7 months). The development of Abs to both MICA and HLA was strongly associated with the development of BOS thereby suggesting a synergistic effect. Furthermore, immune response to mismatched HLA can lead to development of Abs to other MHC related antigens expressed on the airway epithelial cells. Cumulatively, these immune responses contribute to the pathogenesis of chronic rejection following human LTx. Copyright 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211214      PMCID: PMC2874120          DOI: 10.1016/j.humimm.2010.02.021

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  42 in total

Review 1.  Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols.

Authors:  Robert A Montgomery; Mark A Hardy; Stanley C Jordan; Lorraine C Racusen; Lloyd E Ratner; Dolly B Tyan; Andrea A Zachary
Journal:  Transplantation       Date:  2004-07-27       Impact factor: 4.939

2.  Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.

Authors:  S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar
Journal:  J Heart Lung Transplant       Date:  1996-01       Impact factor: 10.247

3.  Immunologic monitoring in lung allograft recipients.

Authors:  L L Schulman; E K Ho; E F Reed; C McGregor; C R Smith; E A Rose; N M Suciu-Foca
Journal:  Transplantation       Date:  1996-01-27       Impact factor: 4.939

4.  Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.

Authors:  Ingo Kaczmarek; Marcus-Andre Deutsch; Teresa Kauke; Andres Beiras-Fernandez; Michael Schmoeckel; Calin Vicol; Ralf Sodian; Bruno Reichart; Michael Spannagl; Peter Ueberfuhr
Journal:  Exp Clin Transplant       Date:  2008-09       Impact factor: 0.945

5.  Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction.

Authors:  Takekazu Iwata; Alexander Philipovskiy; Amanda J Fisher; Robert G Presson; Masako Chiyo; Jae Lee; Elizabeth Mickler; Gerald N Smith; Irina Petrache; David B Brand; William J Burlingham; Bagavathi Gopalakrishnan; Daniel S Greenspan; Jason D Christie; David S Wilkes
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

6.  MICA polymorphisms and decreased expression of the MICA receptor NKG2D contribute to idiopathic pulmonary fibrosis susceptibility.

Authors:  Arnoldo Aquino-Galvez; Martha Pérez-Rodríguez; Angel Camarena; Ramces Falfan-Valencia; Víctor Ruiz; Martha Montaño; Lourdes Barrera; Isabel Sada-Ovalle; Remedios Ramírez; Julio Granados; Annie Pardo; Moisés Selman
Journal:  Hum Genet       Date:  2009-04-12       Impact factor: 4.132

7.  Anti-MICA antibodies are related to adverse outcome in heart transplant recipients.

Authors:  Teresa Kauke; Ingo Kaczmarek; Andrea Dick; Michael Schmoeckel; Marcus-Andre Deutsch; Andres Beiras-Fernandez; Bruno Reichart; Michael Spannagl
Journal:  J Heart Lung Transplant       Date:  2009-04       Impact factor: 10.247

8.  A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation.

Authors:  J D Cooper; M Billingham; T Egan; M I Hertz; T Higenbottam; J Lynch; J Mauer; I Paradis; G A Patterson; C Smith
Journal:  J Heart Lung Transplant       Date:  1993 Sep-Oct       Impact factor: 10.247

9.  Alloantibodies in heart transplantation.

Authors:  Eric K Ho; George Vlad; Adriana I Colovai; E Rodica Vasilescu; Joseph Schwartz; Hugo Sondermeijer; Elizabeth Burke; Charles C Marboe; Silviu Itescu; Nicole Suciu-Foca; Donna Mancini
Journal:  Hum Immunol       Date:  2009-06-23       Impact factor: 2.850

10.  Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease.

Authors:  E F Reed; B Hong; E Ho; P E Harris; J Weinberger; N Suciu-Foca
Journal:  Transplantation       Date:  1996-02-27       Impact factor: 4.939

View more
  17 in total

1.  Update on Chronic Lung Allograft Dysfunction.

Authors:  Jason M Gauthier; Ramsey R Hachem; Daniel Kreisel
Journal:  Curr Transplant Rep       Date:  2016-08-02

2.  Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation.

Authors:  Dilip S Nath; Nataraju Angaswamy; Haseeb Ilias Basha; Donna Phelan; Nader Moazami; Gregory A Ewald; T Mohanakumar
Journal:  Hum Immunol       Date:  2010-09-21       Impact factor: 2.850

Review 3.  Diagnosis, Pathophysiology and Experimental Models of Chronic Lung Allograft Rejection.

Authors:  Jason M Gauthier; Daniel Ruiz-Pérez; Wenjun Li; Ramsey R Hachem; Varun Puri; Andrew E Gelman; Daniel Kreisel
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

Review 4.  Non-MHC antigenic targets of the humoral immune response in transplantation.

Authors:  Qiuheng Zhang; Elaine F Reed
Journal:  Curr Opin Immunol       Date:  2010-09-15       Impact factor: 7.486

Review 5.  Role of antibodies to self-antigens in chronic allograft rejection: potential mechanism and therapeutic implications.

Authors:  Nayan J Sarma; Venkataswarup Tiriveedhi; Nataraju Angaswamy; T Mohanakumar
Journal:  Hum Immunol       Date:  2012-07-10       Impact factor: 2.850

6.  Inhibition of B cell-dependent lymphoid follicle formation prevents lymphocytic bronchiolitis after lung transplantation.

Authors:  Natalia F Smirnova; Thomas M Conlon; Carmela Morrone; Peter Dorfmuller; Marc Humbert; Georgios T Stathopoulos; Stephan Umkehrer; Franz Pfeiffer; Ali Ö Yildirim; Oliver Eickelberg
Journal:  JCI Insight       Date:  2019-02-07

7.  Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Methods Mol Biol       Date:  2013

Review 8.  Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection.

Authors:  Nataraju Angaswamy; Venkataswarup Tiriveedhi; Nayan J Sarma; Vijay Subramanian; Christina Klein; Jason Wellen; Surendra Shenoy; William C Chapman; T Mohanakumar
Journal:  Hum Immunol       Date:  2013-07-19       Impact factor: 2.850

Review 9.  Natural killer cells in lung transplantation.

Authors:  Daniel R Calabrese; Lewis L Lanier; John R Greenland
Journal:  Thorax       Date:  2018-10-31       Impact factor: 9.139

10.  Immune response to tissue-restricted self-antigens induces airway inflammation and fibrosis following murine lung transplantation.

Authors:  V Subramanian; S Ramachandran; B Banan; A Bharat; X Wang; N Benshoff; D Kreisel; A E Gelman; T Mohanakumar
Journal:  Am J Transplant       Date:  2014-09-12       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.